Recent Press Releases

Cortendo to raise $11 mln in private placement

Cortendo has agreed to a private placement with HealthCap, the Third Swedish National Pension Fund, Storebrand and Arctic Fund Management. According to terms of the transaction, Cortendo will raise...

Chimerix Announces Commencement of Public Offering of Common Stock

DURHAM, N.C., Oct. 29, 2014 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it intends to...

Regulus Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif. -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public...

U.S. FDA Approves Once-Daily XIGDUO™ XR Tablets for Adults with Type 2 Diabetes

WILMINGTON, Del.--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration has approved once-daily XIGDUO™ XR (dapagliflozin and metformin hydrochloride...

Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology

Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago...

Lilly Shares Insights from Decade-Long Technology Transfer Experience

New white paper documents Lilly's philanthropic effort to expand access to multidrug-resistant tuberculosis medicines

INDIANAPOLIS

Johnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances

QUEENSLAND, Australia, Oct. 29, 2014 /PRNewswire/ -- Johnson & Johnson Innovation today announced the opening of the Asia Pacific Innovation Center, located in Shanghai with satellites in...

Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease

Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014 MONROVIA, Calif. -- Xencor, Inc....

Cara Therapeutics Announces Positive Results from Human Abuse Liability Trial of I.V. CR845

Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p < 0.0001) in scores for "drug liking," as well as "feeling high",...

Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans

Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018

NEW YORK,

ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections

MUNICH, Germany I October 28, 2014 I ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, announces today the completion of a EUR 7.5 million Series A financing...

Cerulean Announces Management Changes

October 27, 2014 16:01 ET | Source: Cerulean Pharma Inc. CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today...

Advent Life Sciences Raises £145.5M (USD 235M) for its Second Life Sciences Venture Capital Fund

Advent Life Sciences Raises £145.5M (USD 235M) for its Second Life Sciences Venture Capital Fund London, UK, October 28 2014. - Advent Life Sciences today announced the closing of Advent Life...

New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors

LOS ANGELES and SHANGHAI, Oct. 28. 2014 /PRNewswire/ -- The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the...

Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy

Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy (NEW YORK and CAMBRIDGE, UK – October 28, 2014) -...

Zogenix Acquires U.K.-Based Brabant Pharma

Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy Plans to initiate Phase 3 clinical studies of...

Syros Pharmaceuticals Closes $53 Million Series B Financing

WATERTOWN, Mass.--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, announced today that it has closed...